Endo Reiterates US Generics Environment Is ‘Challenging’

Follows Recent Comments By Sandoz And Teva

 
• By Dean Rudge

Endo’s non-injectable Generics revenues plunged by 28% in Q1, in part due to competitive challenges in the US generics sector that management said would continue through 2021.

chart
Endo sees a "fair amount of competition impact" in 2021 • Source: Shutterstock

Endo International plc says its outlook for the company’s portfolio of non-injectable generic products in the US “is a challenging one for 2021,” amid growing debate over competition and pricing trends.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products